{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:10:11Z","timestamp":1790298611203,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004769","name":"Universit\u00e0 degli Studi di Pavia","doi-asserted-by":"publisher","award":["2023-2027"],"award-info":[{"award-number":["2023-2027"]}],"id":[{"id":"10.13039\/501100004769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004769","name":"Universit\u00e0 degli Studi di Pavia","doi-asserted-by":"publisher","award":["20140003980"],"award-info":[{"award-number":["20140003980"]}],"id":[{"id":"10.13039\/501100004769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021016","name":"Istituto di Ricovero e Cura a Carattere Scientifico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007365","name":"Fondazione IRCCS Policlinico San Matteo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Governo Italiano Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.modpat.2025.100825","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T20:00:18Z","timestamp":1750276818000},"page":"100825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["HER2, HER3, and Mismatch Repair Protein Expression in Stage IV Small Bowel Adenocarcinoma: Results From a Multicenter Series"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-7032","authenticated-orcid":false,"given":"Alessandro","family":"Vanoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"De Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Quaquarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rondell Patrell","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Moens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"De Hertogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Guerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Riboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Alberizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pedrazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Vincenzo","family":"Lenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Klersy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Paulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2025.100825_bib1","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2693::AID-CNCR14>3.0.CO;2-U","article-title":"Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995","volume":"86","author":"Howe","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.modpat.2025.100825_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.gtc.2016.04.004","article-title":"Small bowel adenocarcinoma","volume":"45","author":"Aparicio","year":"2016","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.modpat.2025.100825_bib3","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.6004\/jnccn.2019.7344","article-title":"Small bowel adenocarcinoma: etiology, presentation, and molecular alterations","volume":"17","author":"Pedersen","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.modpat.2025.100825_bib4","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.modpat.2025.100825_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","article-title":"Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years","volume":"249","author":"Bilimoria","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.modpat.2025.100825_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00535-019-01636-z","article-title":"Trends in incidence of small bowel cancer according to histology: a population-based study","volume":"55","author":"Bouvier","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.modpat.2025.100825_bib7","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.3390\/cancers14092268","article-title":"Epidemiology, risk factors and diagnosis of small bowel adenocarcinoma","volume":"14","author":"Aparicio","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.modpat.2025.100825_bib8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1245\/s10434-011-2173-6","article-title":"A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease","volume":"19","author":"Overman","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/DCR.0000000000000562","article-title":"Treatment and survival of small-bowel adenocarcinoma in the United States: a comparison with colon cancer","volume":"59","author":"Young","year":"2016","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.modpat.2025.100825_bib10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.6004\/jnccn.2019.0043","article-title":"Small bowel adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Benson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.modpat.2025.100825_bib11","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1002\/cam4.3266","article-title":"Efficacy of surgery and chemotherapy for stage IV small bowel adenocarcinoma: a population-based analysis using surveillance, epidemiology, and end result program database","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.modpat.2025.100825_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0631","article-title":"Evaluation of systemic treatments of small intestinal adenocarcinomas: a systematic review and meta-analysis","volume":"6","author":"De Back","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.modpat.2025.100825_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib14","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41379-020-0497-0","article-title":"PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability","volume":"33","author":"Giuffrida","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2025.100825_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ecco-jcc\/jjz135","article-title":"Clinicopathological and molecular characterisation of Crohn's disease-associated small bowel adenocarcinomas","volume":"14","author":"Liao","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.modpat.2025.100825_bib16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3390\/cancers14051287","article-title":"Molecular landscape of small bowel adenocarcinoma","volume":"14","author":"Pandya","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.modpat.2025.100825_bib17","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1158\/1078-0432.CCR-21-0159","article-title":"ZEBRA: a multicenter phase II study of pembrolizumab in patients with advanced small-bowel adenocarcinoma","volume":"27","author":"Pedersen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2025.100825_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41416-024-02687-7","article-title":"Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases","volume":"131","author":"Aparicio","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.modpat.2025.100825_bib19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.bjc.6605449","article-title":"Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine","volume":"102","author":"Overman","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.modpat.2025.100825_bib20","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1038\/bjc.2013.677","article-title":"Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study","volume":"109","author":"Aparicio","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.modpat.2025.100825_bib21","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-20-2892","article-title":"Characterization and clinical outcomes of DNA mismatch repair-deficient small bowel adenocarcinoma","volume":"27","author":"Latham","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2025.100825_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the phase II DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib23","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib24","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I\/II trial","volume":"41","author":"Krop","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2217\/fon-2022-1250","article-title":"HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC","volume":"19","author":"Yu","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104098","article-title":"Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis","volume":"10","author":"Fujii","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.modpat.2025.100825_bib28","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaoncol.2017.1051","article-title":"Genomic profiling of small-bowel adenocarcinoma","volume":"3","author":"Schrock","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib29","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1007\/s00432-022-04521-0","article-title":"Driver and targetable alterations in Chinese patients with small bowel carcinoma","volume":"149","author":"Li","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00428-013-1425-1","article-title":"Korean Small Intestinal Cancer Study Group. HER2 protein expression and HER2 gene amplification are infrequent in small intestinal carcinomas","volume":"462","author":"Gu","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1016\/j.modpat.2025.100825_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/(SICI)1096-9098(199602)61:2<100::AID-JSO3>3.0.CO;2-G","article-title":"Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA","volume":"61","author":"Zhu","year":"1996","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/ecco-jcc\/jjx031","article-title":"Small bowel carcinomas in coeliac or Crohn's disease: clinico-pathological, molecular, and prognostic features. A study from the small bowel cancer Italian consortium","volume":"11","author":"Vanoli","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.modpat.2025.100825_bib33","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1309\/AJCPK6QHNNOEMJIM","article-title":"Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma","volume":"134","author":"Chan","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.modpat.2025.100825_bib34","series-title":"WHO Classification of Tumours Editorial Board. Digestive System Tumours","first-page":"124","article-title":"Non-ampullary adenocarcinoma","author":"Adsay","year":"2019"},{"key":"10.1016\/j.modpat.2025.100825_bib35","series-title":"Protocol for the examination of specimens from patients with carcinoma of the small intestine","author":"Burgart","year":"2021"},{"key":"10.1016\/j.modpat.2025.100825_bib36","first-page":"947","article-title":"Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting","volume":"485","author":"Grillo","year":"2023","journal-title":"Virchows Arch"},{"key":"10.1016\/j.modpat.2025.100825_bib37","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2025.100825_bib38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.modpat.2025.100825_bib39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100654","article-title":"Evidence for unified assessment criteria of HER2 immunohistochemistry in colorectal carcinoma","volume":"38","author":"Evans","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2025.100825_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155550","article-title":"Understanding the spectrum of HER2 status in breast cancer: from HER2-positive to ultra-low HER2","volume":"262","author":"Ahuja","year":"2024","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.modpat.2025.100825_bib42","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib43","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.modpat.2025.100825_bib44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s40425-019-0788-5","article-title":"Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI\/dMMR status","volume":"7","author":"Loupakis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.modpat.2025.100825_bib45","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.modpat.2025.100825_bib46","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.3390\/cancers16183145","article-title":"Prognostic and predictive roles of HER2 status in non-breast and non-gastroesophageal carcinomas","volume":"16","author":"Quaquarini","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.modpat.2025.100825_bib47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3892\/ol.2023.14197","article-title":"Successful treatment with trastuzumab plus chemotherapy as the first line regimen in advanced small bowel adenocarcinoma harboring HER2 amplification: a report of two cases","volume":"27","author":"Wang","year":"2023","journal-title":"Oncol Lett"},{"key":"10.1016\/j.modpat.2025.100825_bib48","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ejca.2014.04.007","article-title":"ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma","volume":"50","author":"Laforest","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.modpat.2025.100825_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12876-019-0942-z","article-title":"Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma","volume":"19","author":"Quaas","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.modpat.2025.100825_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007200","article-title":"Exome-wide somatic mutation characterization of small bowel adenocarcinoma","volume":"14","author":"H\u00e4nninen","year":"2018","journal-title":"PLoS Genet"},{"key":"10.1016\/j.modpat.2025.100825_bib51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12920-023-01736-z","article-title":"Genetic profile of Chinese patients with small bowel cancer categorized by anatomic location","volume":"16","author":"Shi","year":"2023","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.modpat.2025.100825_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100790","article-title":"Targeting HER3 for cancer treatment: a new horizon for an old target","volume":"8","author":"Uliano","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.modpat.2025.100825_bib53","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0959-8049(97)00244-X","article-title":"c-erbB-3 protein expression in ductal carcinoma in situ of the breast","volume":"33","author":"Bobrow","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.modpat.2025.100825_bib54","doi-asserted-by":"crossref","first-page":"M199","DOI":"10.1136\/mp.49.4.M199","article-title":"c-erbB3 protein expression in ovarian cancer","volume":"49","author":"Rajkumar","year":"1996","journal-title":"Clin Mol Pathol"},{"key":"10.1016\/j.modpat.2025.100825_bib55","first-page":"142","article-title":"High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas","volume":"10","author":"Yi","year":"1997","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2025.100825_bib56","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1073\/pnas.88.17.7792","article-title":"Differential expression of epidermal growth factor-related proteins in human colorectal tumors","volume":"88","author":"Ciardiello","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.modpat.2025.100825_bib57","first-page":"1413","article-title":"Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression","volume":"1","author":"Friess","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2025.100825_bib58","first-page":"2727","article-title":"Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis","volume":"18","author":"Slesak","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.modpat.2025.100825_bib59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.mam.2015.07.001","article-title":"Targeting HER (ERBB) signaling in head and neck cancer: an essential update","volume":"45","author":"Zhang","year":"2015","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.modpat.2025.100825_bib60","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1046\/j.1464-410X.1997.30412.x","article-title":"A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma","volume":"79","author":"Leung","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.modpat.2025.100825_bib61","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-08-0186","article-title":"HER3 is a determinant for poor prognosis in melanoma","volume":"14","author":"Reschke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2025.100825_bib62","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00428-015-1747-2","article-title":"HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value","volume":"466","author":"Seo","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.modpat.2025.100825_bib63","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Holbro","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.modpat.2025.100825_bib64","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.modpat.2025.100825_bib65","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10911-008-9083-7","article-title":"ERBB3\/HER3 and ERBB2\/HER2 duet in mammary development and breast cancer","volume":"13","author":"Stern","year":"2008","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.modpat.2025.100825_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110291","article-title":"Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers","volume":"38","author":"Campbell","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.modpat.2025.100825_bib67","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/path.1711700309","article-title":"Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1","volume":"170","author":"Rajkumar","year":"1993","journal-title":"J Pathol"},{"key":"10.1016\/j.modpat.2025.100825_bib68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/djs501","article-title":"HER3 overexpression and survival in solid tumors: a meta-analysis","volume":"105","author":"Ocana","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.modpat.2025.100825_bib69","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1111\/cas.15119","article-title":"Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma","volume":"112","author":"Pan","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.modpat.2025.100825_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00243","article-title":"ERBB3-activating mutations in small bowel adenocarcinomas","volume":"2","author":"Cabel","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.modpat.2025.100825_bib71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10689-015-9856-2","article-title":"Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis","volume":"15","author":"Haraldsdottir","year":"2016","journal-title":"Fam Cancer"},{"key":"10.1016\/j.modpat.2025.100825_bib72","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1600-0463.2009.02543.x","article-title":"Differential expression of hMLH1 in sporadic human colorectal cancer tumors and distant metastases","volume":"117","author":"Larsen","year":"2009","journal-title":"APMIS"},{"key":"10.1016\/j.modpat.2025.100825_bib73","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.3390\/ijms23084427","article-title":"Heterogeneity of mismatch repair status and microsatellite instability between primary tumour and metastasis and its implications for immunotherapy in colorectal cancers","volume":"23","author":"Evrard","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.modpat.2025.100825_bib74","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190730","article-title":"Mismatch repair status between primary colorectal tumor and metastatic tumor, a retrospective consistent study","volume":"39","author":"Wang","year":"2019","journal-title":"Biosci Rep"},{"key":"10.1016\/j.modpat.2025.100825_bib75","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4132\/jptm.2016.12.09","article-title":"Comparison of the mismatch repair system between primary and metastatic colorectal cancers using immunohistochemistry","volume":"51","author":"Jung","year":"2017","journal-title":"J Pathol Transl Med"},{"key":"10.1016\/j.modpat.2025.100825_bib76","first-page":"163","article-title":"HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis","volume":"27","author":"Peng","year":"2015","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.modpat.2025.100825_bib77","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cam4.228","article-title":"Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases","volume":"3","author":"Lee","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.modpat.2025.100825_bib78","doi-asserted-by":"crossref","first-page":"15065","DOI":"10.18632\/oncotarget.3527","article-title":"HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer","volume":"6","author":"Styczen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.modpat.2025.100825_bib79","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.critrevonc.2012.05.002","article-title":"Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers","volume":"84","author":"Vignot","year":"2012","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522500122X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522500122X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T21:51:06Z","timestamp":1763502666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089339522500122X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":78,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S089339522500122X"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100825","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2, HER3, and Mismatch Repair Protein Expression in Stage IV Small Bowel Adenocarcinoma: Results From a Multicenter Series","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100825","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100825"}}